{"nctId":"NCT00868166","briefTitle":"Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS","startDateStruct":{"date":"2009-04-30","type":"ACTUAL"},"conditions":["Amyotrophic Lateral Sclerosis"],"count":512,"armGroups":[{"label":"Olesoxime","type":"EXPERIMENTAL","interventionNames":["Drug: Olesoxime","Drug: Riluzole"]},{"label":"Placebo Comparator","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Comparator","Drug: Riluzole"]}],"interventions":[{"name":"Olesoxime","otherNames":["TRO19622"]},{"name":"Placebo Comparator","otherNames":["Placebo"]},{"name":"Riluzole","otherNames":["Rilutek"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with sporadic or familial Amyotrophic Lateral Sclerosis\n* Patients with a clinical diagnosis of laboratory-supported probable, probable, or definite ALS according to the modified El Escorial criteria8.\n* Have signed an Informed Consent to participate to the trial before any study related procedure has taken place.\n* Be of age \\>18 (exclusive) and \\< 80 years (inclusive).\n* If a female, not lactating, has a negative pregnancy test and agrees to use an effective method of birth control.\n* Onset of ALS Symptoms (weakness) for more than 6 months (inclusive) and less than 36 months(inclusive).\n* Slow vital capacity (SVC), measured three times, one of the measure being \\>/= 70% of that predicted.\n* Treated with riluzole at the stable dose of 50 mg bid for at least 30 days before enrolment.\n\nExclusion Criteria:\n\n* Tracheostomy, invasive ventilation, or non invasive positive pressure ventilation (NIPPV).\n* Gastrostomy.\n* Evidence of major psychiatric disorder or clinically evident dementia.\n* Diagnosis of a neurodegenerative disease in addition to ALS.\n* Have a current medication that could interfere with TRO19622 pharmacokinetics: tamoxifene.\n* Have current medications that could interfere with TRO19622 absorption such as ezetimibe, bile salts chelators (cholesteramine), fibrates, phytosterols, niacin (vitamin B3),fish oils. Have a current medication of lipid lowering agents other than statins.\n* Known hypersensitivity to any component of the study drug.\n* Patients with known intolerance or contra-indication to riluzole.\n* Have a recent history (within the previous 6 months) or current evidence of alcohol or drug abuse.\n* Have concurrent unstable disease involving any system eg, carcinoma other than basal cell carcinoma, any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of Coronary Artery Disease, or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation.\n\n  . In Germany: Have any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of Coronary Artery Disease or any cardiovascular illness known or identified at the screening or inclusion visits, or have concurrent unstable disease involving any system eg, carcinoma other than basal cell carcinoma or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation.\n* Having a baseline QTc (Bazett) \\> 450 msec for males and \\> 470 msec for females.\n* Patients with known hepatitis B/C or HIV positive serology.\n* Be pregnant female or lactating.\n* Have renal impairment defined as blood creatinine \\> 1:5 X upper limit of normal.\n* Have hepatic impairment and/or liver enzymes (ALAT or ASAT) \\> 3 X ULN.\n* Hemostasis disorders or current treatment with oral anticoagulants.\n* Be possibly dependent on the Investigator or the Sponsor (eg, including, but not limited to, affiliated employee).\n* Participated in any other investigational drug or therapy study with a non approved medication, within the previous 3 months.\n* Patients without Social Security Insurance (France).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival Rate at 18 Months","description":"Overall survival was defined from the date of randomization until the date of death (event) or last known alive date (censored). If the death date was after 18 months, the participant was censored at 18 months (548 days). Participants still alive at or after 18 months were censored at 18 months/ 548 days. All data over the 18-month follow-up period after randomization, and participant survival status at the 18-month follow-up visit for participants who withdrew prematurely from the study for reasons other than death were included.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"69.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Failure Over 18 Months","description":"Time to failure was defined as the time from randomization to the time of the first event to consider (Tracheostomy, invasive ventilation \\[IV\\] or non invasive ventilation \\[NIV\\])","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)","description":"The ALSFRS-R is an ordinal rating scale (0 through 4) used to determine the ALS participant's self assessment of their ability and need for assistance in 12 activities or functions. This is a validated scale, both in person and by phone, which provides a total score from four sub-scores which assess speech and swallowing, (bulbar function), use of upper extremities (cervical function), gait and turning in bed (lumbar function), and breathing (respiratory function). Total scores range from 0 (most impaired) to 48 (normal ability).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":"4.78"},{"groupId":"OG001","value":"38.2","spread":"5.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":"5.46"},{"groupId":"OG001","value":"37.2","spread":"5.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":"5.64"},{"groupId":"OG001","value":"36.7","spread":"6.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":"6.29"},{"groupId":"OG001","value":"35.3","spread":"6.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":"7.11"},{"groupId":"OG001","value":"33.1","spread":"7.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":"7.72"},{"groupId":"OG001","value":"30.4","spread":"8.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":"8.34"},{"groupId":"OG001","value":"28.8","spread":"8.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"8.56"},{"groupId":"OG001","value":"27.6","spread":"8.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":"9.38"},{"groupId":"OG001","value":"26.3","spread":"9.13"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Global ALS FRS-R Score of <30 or Death","description":"Percentage of participants with a global ALS FRS-R score of \\< 30 or death was estimated using the Kaplan-Meier method in the ITT, with a two-tailed log-rank, both stratified by site of onset (bulbar or spinal) and non-stratified. The ALSFRS-R is an ordinal rating scale (0 through 4) used to determine the ALS participant's self assessment of their ability and need for assistance in 12 activities or functions. This is a validated scale, both in person and by phone, which provides a total score from four sub-scores which assess speech and swallowing, (bulbar function), use of upper extremities (cervical function), gait and turning in bed (lumbar function), and breathing (respiratory function). Total scores range from 0 (most impaired) to 48 (normal ability).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","spread":null},{"groupId":"OG001","value":"24.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Slow Vital Capacity (SVC) Percent Predicted","description":"SVC as a percent of the predicted value was evaluated and reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":"14.6"},{"groupId":"OG001","value":"93.1","spread":"15.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":"17.8"},{"groupId":"OG001","value":"89.7","spread":"17.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":"20.4"},{"groupId":"OG001","value":"85.7","spread":"19.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.7","spread":"22.9"},{"groupId":"OG001","value":"80.5","spread":"22.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.9","spread":"24.3"},{"groupId":"OG001","value":"75.5","spread":"24.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":"25.4"},{"groupId":"OG001","value":"71.3","spread":"29.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":"28.8"},{"groupId":"OG001","value":"71.4","spread":"27.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":"27.6"},{"groupId":"OG001","value":"67.1","spread":"25.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"31.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups","description":"MMT score involved the examination of 30 items. These 30 items are scored from 0 (no trace of contraction) to 5 (normal power at first try). The global score is the sum of the item scores and can range from 0 to 150. Higher score indicates some power.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":"18.0"},{"groupId":"OG001","value":"126","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":"22.8"},{"groupId":"OG001","value":"120","spread":"22.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":"24.4"},{"groupId":"OG001","value":"114","spread":"24.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":"27.1"},{"groupId":"OG001","value":"109","spread":"27.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":"29.7"},{"groupId":"OG001","value":"103","spread":"29.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":"32.0"},{"groupId":"OG001","value":"99.2","spread":"31.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":"33.7"},{"groupId":"OG001","value":"91.8","spread":"34.7"}]}]}]},{"type":"SECONDARY","title":"The Single-Item Mc Gill Quality of Life Scale","description":"The single-item McGill quality of life scale evaluated the following question \"Considering all parts of my life - physical, emotional, social, spiritual, and financial - over the past two (2) days, the quality of my life has been…\"as a score of 1 to 10 on a visual analog scale where 0 is very bad and 10 is excellent.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.51","spread":"1.65"},{"groupId":"OG001","value":"6.47","spread":"1.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.17","spread":"1.73"},{"groupId":"OG001","value":"6.27","spread":"1.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.83","spread":"1.98"},{"groupId":"OG001","value":"5.75","spread":"1.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.55","spread":"2.12"},{"groupId":"OG001","value":"5.50","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.30","spread":"2.14"},{"groupId":"OG001","value":"5.25","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.97","spread":"2.11"},{"groupId":"OG001","value":"5.10","spread":"2.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.96","spread":"2.26"},{"groupId":"OG001","value":"4.90","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.77","spread":"2.29"},{"groupId":"OG001","value":"5.01","spread":"2.16"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":68,"n":259},"commonTop":["Nasopharyngitis","Fall","Diarrhoea","Headache","Nausea"]}}}